Bivalirudin Tops Treatment Standard In STEMI Patients Undergoing PCI

WASHINGTON DC- Bivalirudin (AngiomaxR) is more effective than conventional therapy involving heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), according to updated results of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.